2BO Stock Chart & Stats
€2.04
-€0.06(-3.23%)
At close: 4:00 PM EDT
€2.04
-€0.06(-3.23%)
Day’s Range― - ―
52-Week Range€1.07 - €4.44
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
€38.90M
Enterprise Value€11.97M
Total Cash (Recent Filing)€23.02M
Total Debt (Recent Filing)€3.21M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 18, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume58
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.45Price Target Upside314.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces mandatory financing costs and preserves flexibility while Serina develops its pipeline. The current capital structure is less burdened by debt service, allowing available resources to remain focused on research, clinical development, and platform advancement.
Platform And Commercial ExpertiseAdding a director with biopharmaceutical commercialization and business-development experience strengthens governance around SER-252 and the broader POZ platform. That expertise could improve clinical, partnering, and commercial strategy as the company advances toward potential value-creating milestones.
Simplified Capital StructureRemoving the former preferred-stock designation simplifies the equity structure and clarifies the rights of existing common shareholders. It also gives Serina cleaner corporate documentation and greater flexibility to structure future financing or preferred issuances without an outstanding Series A overhang.
Bears Say
No Current Commercial RevenueThe absence of TTM revenue confirms that Serina remains dependent on development progress rather than an established commercial business. Deep operating losses reduce earnings quality and leave future value dependent on successful execution, regulatory advancement, and eventual product monetization.
Persistent Cash BurnLarge operating and free-cash-flow deficits indicate that reported losses are translating into substantial cash outflows. Continued burn can constrain development capacity and make recurring external financing necessary, increasing the importance of capital access and disciplined spending over the next several quarters.
Equity And Dilution RiskHistorical periods of negative equity indicate that the balance sheet has not been consistently durable despite currently low debt. Combined with ongoing losses and reliance on equity financing, this creates a lasting risk that future capital needs will dilute existing holders or weaken per-share ownership.
Serina Therapeutics News
2BO FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was €1.07 and its highest was €4.44 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is €38.90M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 30 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.473 earnings per share for the quarter, missing the consensus estimate of -€0.4 by -€0.072.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 25,400,473 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -€0.473 in its last earnings report, missing expectations of -€0.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in DE:2BO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.45 (314.42% Upside)
€8.45 (314.42% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.82%
12-Months-Change
Fundamentals
Return on Equity
-222.42%
Trailing 12-Months
Asset Growth
188.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
2BO Stock 12 Month Forecast
Average Price Target
€8.45
▲(314.42% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
―
Jupiter Neurosciences, Inc.
―